Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke
Group Managing Director, Kate Quirke
Source: Alcidion Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) expands the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD)
  • The contract extension will generate around an additional $1.8 million in revenue over the next three years
  • Last year, the parties signed a 12 month contract with Sydney LHD to manage the care of COVID-19 patients in home isolation
  • Alongside this contract, Alcidion and Sydney LHD will work together to deploy the patient app, Miya Care
  • Alcidion is up 4.29 per cent and is trading at 36.5 cents per share at 1:45 pm AEDT

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).

The contract extension will generate an additional estimated $1.8 million in revenue over the next three years.

Last year, the parties signed a 12 month contract with Sydney LHD for Miya. The agreement was established to manage the care of COVID-19 patients in home isolation.

Miya provides RPA Virtual Hospital (rpavirtual) clinicians with a clinical monitoring dashboard that consolidates information to support remote patient care. The technology aims to reduce required hospitalisations, support an increase in the numbers of patients who can be treated and improve recovery outcomes.

Alongside this contract, Alcidion and Sydney LHD will work together to deploy the patient app, Miya Care.

Speaking on this announcement is Managing Director Kate Quirke.

“We are very excited to build on our initial implementation of Miya Precision with Sydney Local Health District through this project that highlights the flexibility and scalability of our platform as a key enabler of new and innovative models of care,” Ms Quirke said.

“We believe Alcidion can play a meaningful role in the development of virtual care across the hospital system in Australia and this partnership with Sydney Local Health District provides a strong validation of that.”

Alcidion was up 4.29 per cent, trading at 36.5 cents per share at 1:45 pm AEDT.

ALC by the numbers
More From The Market Online

Universal Biosensors surges 60% on FDA approval for Class II device

Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical…

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…